AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3535980
Drug: Applied relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied relaxation training (ART) taught during one session using participant demonstration, written instructions, taped instructions, or a combination of all three; practice at home encouraged.
Trial: 28295581
Drug: Prolonged-release tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tacrolimus (initial dose: 0.2 mg/kg/day)
Trial: 28295581
Drug: Immediate-release tacrolimus
RxNorm normalized name: tacrolimus Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tacrolimus (initial dose: 0.1 mg/kg/day)
Trial: 23569311
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg with docetaxel 100 mg/m(2) and trastuzumab 8 mg/kg loading dose followed by 6 mg/kg, administered every 3 weeks
Trial: 23569311
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m(2) and trastuzumab 8 mg/kg loading dose followed by 6 mg/kg without bevacizumab, administered every 3 weeks
Trial: 23569311
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg with docetaxel and trastuzumab
Trial: 23569311
Drug: Bevacizumab-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab-containing therapy
Trial: 19500335
Drug: Infliximab (anti-TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (anti-TNF therapy)
Trial: 14699862
Drug: L dose
RxNorm normalized name: Medrol Dosepak
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L dose group (8 mumol Fe/kg)
Trial: 14699862
Drug: H dose
RxNorm normalized name: Qvar with Dose Counter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H dose group (12 mumol Fe/kg)
Trial: 8893144
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol (0.25 microgram/day)
Trial: 1709686
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by pelvic radiotherapy (CT + RT; arm B) - three cycles of chemotherapy (BOMP: bleomycin, vincristine, mitomycin, and cisplatin) followed by RT
Trial: 6402369
Drug: Oral MESNA
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral MESNA (840 mg/m2 at 0 hr, 4 hr, and 8 hr p.i.)
Trial: 28535076
Drug: Cingal (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cingal (4 mL, 88 mg hyaluronic acid plus 18 mg triamcinolone hexacetonide)
Trial: 28535076
Drug: Monovisc (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovisc (4 mL, 88 mg hyaluronic acid)
Trial: 28535076
Drug: Saline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (4 mL, 0.9%)
Trial: 24804695
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (intramuscular testosterone undecanoate for 40 weeks)
Trial: 23122652
Drug: Alemtuzumab 12
RxNorm normalized name: alemtuzumab 12 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab 12 mg per day (IV)
Trial: 23122652
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta 1a 44 μg (SC)
Trial: 20573586
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT) in CP+NGT group
Trial: 20573586
Drug: Intravenous Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Glucose Tolerance Test (IVGTT) in CP+NGT group
Trial: 20573586
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT) in CP+IGT group
Trial: 20573586
Drug: Intravenous Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Glucose Tolerance Test (IVGTT) in CP+IGT group
Trial: 20573586
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT) in CP+DM group
Trial: 20573586
Drug: Intravenous Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Glucose Tolerance Test (IVGTT) in CP+DM group
Trial: 20573586
Drug: Oral Glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Glucose Tolerance Test (OGTT) in healthy subjects
Trial: 20573586
Drug: Intravenous Glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Glucose Tolerance Test (IVGTT) in healthy subjects
Trial: 15625138
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral furosemide daily for 5 days with oral potassium supplementation
Trial: 20881606
Drug: amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine 5 mg/d
Trial: 10492056
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with alpha1‐AGP levels over 0.9 mg/ml
Trial: 10492056
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with alpha1‐AGP levels less than 0.7 mg/ml
Trial: 8942423
Drug: Vitamins C
RxNorm normalized name: MULTIVITAMINS CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins C and E (1 g ascorbic acid and 400 mg dl-alpha-tocopheryl acetate)
Trial: 8942423
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 mg dl-alpha-tocopheryl acetate)
Trial: 8942423
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1 g ascorbic acid)
Trial: 23118720
Drug: 30% FFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% FFA suppositories
Trial: 17878744
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of alprazolam orally
Trial: 14716761
Drug: Capecitabine at
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at 1250 mg/m² twice daily on Days 2-15 and irinotecan at 300 mg/m² on Day 1 (Arm A)
Trial: 14716761
Drug: Capecitabine at
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at 1250 mg/m² twice daily on Days 2-15 and irinotecan at 150 mg/m² on Days 1 and 8 (Arm B)
Trial: 14716761
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of capecitabine (1000 mg/m²) and irinotecan (Arm A: 240 mg/m²; Arm B: 120 mg/m²)
Trial: 3514082
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg daily, with option to reduce to 10 mg at week 4 or 8)
Trial: 3514082
Drug: Naproxen (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (750 mg daily, with option to reduce to 500 mg at week 4 or 8)
Trial: 3345774
Drug: Adenosine (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (doses of 20, 30, 40, 50, 60, 80 and 100% of the maximum tolerable dose)
Trial: 17071213
Drug: Group behavior
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group behavior therapy (BT)
Trial: 17071213
Drug: Group supportive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group supportive therapy (ST)
Trial: 11093990
Drug: Standard balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard balanced outpatient anesthetic with ondansetron 4 mg (Group II)
Trial: 9373420
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy and maintenance cognitive therapy
Trial: 9373420
Drug: Antidepressants and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants and maintenance antidepressants
Trial: 9373420
Drug: Antidepressants and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants and maintenance cognitive therapy
Trial: 1616387
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (C)
Trial: 3987804
Drug: Enteric-coated pellets
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated pellets of erythromycin base administered 1 hour before breakfast
Trial: 2119396
Drug: Enteric-coated tablets
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated tablets
Trial: 27759625
Drug: Gemifloxacin (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin (320 mg single dose) plus amoxicillin (1g twice daily), bismuth (240 mg), and omeprazole (20 mg) for 14 days
Trial: 27759625
Drug: Gemifloxacin-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin-containing therapy
Trial: 21949432
Drug: Daily low‐pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily low‐pressure pulsatile lavage treatment with 1 L of normal saline at 11 psi of pressure
Trial: 20470671
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg in combination with concurrent radiotherapy (RT) +/‐ concomitant cisplatin
Trial: 20470671
Drug: Gefitinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib and RT with concurrent cisplatin
Trial: 15998268
Drug: Ultrasonic re-treatment
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic re-treatment
Trial: 15998268
Drug: Hand instrumentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand instrumentation re-treatment
Trial: 12921607
Drug: Ordinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary treatment of chronic gastritis (plan A)
Trial: 12921607
Drug: Functional dyspepsia
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional dyspepsia treatment (plan B)
Trial: 9010701
Drug: Morphine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (20 or 30 mg)
Trial: 9010701
Drug: Codeine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (75 or 100 mg)
Trial: 1488756
Drug: Postremission therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postremission therapy without prednisolone (PSL)
Trial: 1488756
Drug: Postremission therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postremission therapy with prednisolone (PSL)
Trial: 30320574
Drug: Music listening
RxNorm normalized name: Listerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music listening (ML)
Trial: 25592742
Drug: Souvenaid™ (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Souvenaid™ (125 ml/day)
Trial: 16357116
Drug: Org 25969
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 25969 0.5 mg kg(‐1)
Trial: 16357116
Drug: Org 25969
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 25969 4.0 mg kg(‐1)
Trial: 16357116
Drug: Org 25969
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 25969 (various doses)
Trial: 16357116
Drug: Org 25969
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 25969 (2-4 mg kg(‐1))
Trial: 12813331
Drug: Low-dose unfractionated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose unfractionated heparin (UFH) 5,000 U every 8 hours
Trial: 8941507
Drug: Coca chewing
RxNorm normalized name: ERYTHROXYLUM COCA LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coca chewing (15 g)
Trial: 1685100
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg of vecuronium
Trial: 1685100
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg of vecuronium
Trial: 1685100
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg of vecuronium
Trial: 1685100
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg of vecuronium
Trial: 6127039
Drug: QH 25
RxNorm normalized name: Quinine Hydrochloride 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QH 25 (0.25, 0.75, and 2.25 mg orally)
Trial: 6127039
Drug: Salbutamol (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (2, 6, and 18 mg orally)
Trial: 28124506
Drug: Metformin up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin up to 1,000 mg twice daily
Trial: 30796338
Drug: Home-based aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based aerobic exercise and resistance training (aerobic exercise thrice weekly and resistance training twice weekly for 12 weeks)
Trial: 18318773
Drug: Udenafil 200
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 200 mg
Trial: 25759565
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of Udenafil and Dapoxetine
Trial: 17159457
Drug: Quetiapine monotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine monotherapy, 300 or 600 mg/day
Trial: 15019892
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy at the time of hospital discharge
Trial: 11260155
Drug: Salmeterol (SM)
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol (SM) 50 microg, twice daily for 1 week
Trial: 9731049
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 (8 weekly infusions) - Arm A
Trial: 9731049
Drug: Rituximab 500
RxNorm normalized name: riTUXimab 500 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 500 mg/m2 (1 infusion followed by 7 weekly infusions) - Arm B
Trial: 8162926
Drug: Naloxone (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.8 mg)
Trial: 28797049
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (BICA) (0.3 g/kg)
Trial: 28797049
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 g NaCl)
Trial: 19149890
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulphate (80 mg/day of elemental iron) for one month
Trial: 12688516
Drug: Antioxidant supplements
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplements (two capsules per day for 4 weeks)
Trial: 12688516
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules per day for 4 weeks)
Trial: 10428158
Drug: 24-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 24-day regimen of low-dose combined oral contraceptive (60 microg gestodene and 15 microg ethinyl estradiol)
Trial: 10428158
Drug: 21-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 21-day regimen of low-dose combined oral contraceptive (60 microg gestodene and 15 microg ethinyl estradiol)
Trial: 2654865
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment (higher initial doses: >= 125 mg of cortisone or >= 100 mg of hydrocortisone)
Trial: 24034663
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg/d, titrated to 10-20 mg/d)
Trial: 19705272
Drug: Pleasantly arousing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleasantly arousing images (e.g., skydiving)
Trial: 19705272
Drug: Unpleasantly arousing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unpleasantly arousing images (e.g., an aimed gun)
Trial: 15211412
Drug: Subcutaneous ring
RxNorm normalized name: RING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous ring block with levobupivacaine
Trial: 15211412
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (2 microg/kg) and paracetamol (30 mg/kg)
Trial: 8002621
Drug: Thrice-weekly injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly injection of Romurutide (3 times per week for 3 weeks)
Trial: 8002621
Drug: Five times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five times per week injection (5 times per week for 2 weeks)
Trial: 8002621
Drug: Thrice-weekly injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly injection of Romurutide
Trial: 21975200
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1-year MRI lesion activity and relapses
Trial: 16392974
Drug: Longest duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longest duration of abstinence achieved during treatment
Trial: 12580650
Drug: CHO-PRO beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-PRO beverage (355 ml; approximately 0.8 g carbohydrate (CHO).kg(-1) body wt and approximately 0.2 g protein.kg(-1) body wt)
Trial: 9049582
Drug: YM17E 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM17E 150 mg twice daily (b.d.)
Trial: 9049582
Drug: YM17E 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM17E 300 mg twice daily (b.d.)
Trial: 7819790
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (Havrix, SKF) - 1 injection at day 0, 1 at D15, booster at 6 months
Trial: 7819790
Drug: Yellow fever
RxNorm normalized name: yellow fever live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yellow fever vaccine - 1 injection at day 0
Trial: 7819790
Drug: Both hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both hepatitis A and yellow fever vaccines
Trial: 30208343
Drug: 12-week stepped
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week stepped collaborative care intervention (cognitive behavioral therapy, CBT)
Trial: 26156512
Drug: Training with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training with protein supplement (n = 18)
Trial: 26156512
Drug: Training with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training with placebo supplement (n = 13)
Trial: 22928719
Drug: Miltefosine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miltefosine (150 mg daily for 4 weeks)
Trial: 20216222
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (400, 600 or 800 mg/day)
Trial: 14666762
Drug: Chinese Compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese Compound Changjitai (CJT)
Trial: 10713623
Drug: MEL-CY (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL-CY (cyclophosphamide 120 mg/kg + melphalan 200 mg/m2)
Trial: 10713623
Drug: MEL-TBI (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEL-TBI (total body irradiation 1125 cGy + melphalan 140 mg/m2)
Trial: 1497051
Drug: Esterified estrogen
RxNorm normalized name: Esterified estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterified estrogen 0.625 mg (Estratab)
Trial: 1497051
Drug: Esterified estrogen
RxNorm normalized name: Esterified estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esterified estrogen 0.625 mg plus 1.25 mg methyltestosterone (Estratest H.S.)
Trial: 1497051
Drug: Conjugated estrogen
RxNorm normalized name: Conjugated estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated estrogen 0.625 mg (Premarin)
Trial: 6689276
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 500 mg of salicylamide
Trial: 6689276
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 500 mg of salicylamide
Trial: 6689276
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 1500 mg of salicylamide
Trial: 6689276
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 1500 mg of salicylamide
Trial: 6689276
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of salicylamide